Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

61. Viberzi - eluxadoline - Irritable bowel syndrome with diarrhea

Viberzi - eluxadoline - Irritable bowel syndrome with diarrhea eluxadoline | CADTH.ca Find the information you need eluxadoline eluxadoline Last Updated: September 18, 2018 Result type: Reports Project Number: SR0560-000 Product Line: Generic Name: eluxadoline Brand Name: Viberzi Manufacturer: Allergan Pharma Co. Indications: Irritable bowel syndrome with diarrhea Manufacturer Requested Reimbursement Criteria 1 : As per the Health Canada-approved indication (for the tretment of irritable bowel (...) and drug plans August 24, 2018 CDEC Final Recommendation posted August 29, 2018 Final CDR review report(s) and patient input posted September 18, 2018 Tags digestive system, gastrointestinal tract, diarrhea, irritable bowel syndrome, irritable bowel; Diarrhea Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

62. Fecal microbiota transplantation for patients with irritable bowel syndrome: a systematic review and meta-analysis protocol

Fecal microbiota transplantation for patients with irritable bowel syndrome: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

63. Therapeutic effects of cannabinoids on motility rates in adults with irritable bowel syndrome: a systematic review

Therapeutic effects of cannabinoids on motility rates in adults with irritable bowel syndrome: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

64. Probiotics for the treatment of irritable bowel syndrome in children [Cochrane protocol]

Probiotics for the treatment of irritable bowel syndrome in children [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

65. Efficacy and safety of glutamine supplements for patients with diarrhea-predominant irritable bowel syndrome: protocol for systematic review and meta-analysis

Efficacy and safety of glutamine supplements for patients with diarrhea-predominant irritable bowel syndrome: protocol for systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

66. Non-pharmacological treatments for irritable bowel syndrome: an umbrella review of systematic reviews and meta-analyses

Non-pharmacological treatments for irritable bowel syndrome: an umbrella review of systematic reviews and meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

67. Irritable bowel syndrome

Irritable bowel syndrome Irritable bowel syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Irritable bowel syndrome Last reviewed: February 2019 Last updated: January 2019 Summary Irritable bowel syndrome symptoms include recurrent abdominal pain or discomfort that is associated with a change in stool frequency or form. The pain or discomfort may be relieved by defecation. It is important to determine whether (...) be individualised and is dependent on the patient's predominant symptoms. Definition Irritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune

2018 BMJ Best Practice

68. Clinical effects and safety of Tong Xie Yao Fang for diarrhea predominant irritable bowel syndrome: a meta-analysis

Clinical effects and safety of Tong Xie Yao Fang for diarrhea predominant irritable bowel syndrome: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

69. Efficacy of Chinese patent medicine in providing relief of diarrhea-predominant irritable bowel syndrome: a literature review of randomized trials

Efficacy of Chinese patent medicine in providing relief of diarrhea-predominant irritable bowel syndrome: a literature review of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

70. Efficacy of complementary and alternative medicine in adults with irritable bowel syndrome: a systematic review of randomized controlled trials

Efficacy of complementary and alternative medicine in adults with irritable bowel syndrome: a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

71. Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study Full Text available with Trip Pro

Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study Irritable bowel syndrome (IBS), as a chronic digestive disorder, impacts extensively on the quality of life, emotional well-being and self-identity. Chronic illness disrupts taken-for-granted notions about self. No qualitative study was found regarding patients' experience of life with irritable bowel syndrome (IBS) in Iran.To explore the self-perception of lived experience of IBS patients.A

2017 Electronic physician

72. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial Full Text available with Trip Pro

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS.We performed a 2×2 factorial trial of 104

2017 EvidenceUpdates

73. Interventions for post-infectious irritable bowel syndrome: a systematic review of treatment efficacy. Full Text available with Trip Pro

Interventions for post-infectious irritable bowel syndrome: a systematic review of treatment efficacy. Post-infectious irritable bowel syndrome (PI-IBS) due to traveler's diarrhea is the second most common illness seen in post-travel clinics, yet its optimal management remains unknown. We performed a systematic review to evaluate treatment efficacy in PI-IBS.We searched Medline, EMBASE, LILACS, CINAHL, CAB abstracts, and the Cochrane Library to February 3, 2014 for intervention studies

2017 Tropical diseases, travel medicine and vaccines

74. Eluxadoline for treating irritable bowel syndrome with diarrhoea

Eluxadoline for treating irritable bowel syndrome with diarrhoea Eluxadoline for treating irritable bowel Eluxadoline for treating irritable bowel syndrome with diarrhoea syndrome with diarrhoea T echnology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents 1 Recommendations 4 2 The technology 5 3

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

75. Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial Full Text available with Trip Pro

Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial IBS is the most common functional disease of the low gastrointestinal tract. Recently, the interest towards a diet approach has increased, for example, a diet with low content of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs). The aim of the present study

2017 Journal of translational internal medicine Controlled trial quality: uncertain

76. Irritable Bowel Syndrome. (Abstract)

Irritable Bowel Syndrome. This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatment, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions

2017 Annals of Internal Medicine

77. Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial (Abstract)

Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial Individual gut-directed hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal pain or functional abdominal pain syndrome (FAP[S]). It is, however, unavailable to many children.To compare the effectiveness of HT by means

2017 EvidenceUpdates

78. Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop Full Text available with Trip Pro

Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop A working theoretical model for irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGIDs) does not exist, hampered by the lack of any clear cut invention that address all symptom and signs of the disease. Reports of cessation of symptom and signs of both major types

2017 Translational gastroenterology and hepatology

79. The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment. Full Text available with Trip Pro

The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment. Hypnotherapy has been reported as being beneficial in the treatment of irritable bowel syndrome (IBS). We aimed to test the hypothesis that patients with IBS treated 'holistically' by hypnosis (i.e. by combined psychological and physiological symptom imagery) would have greater improvement in their IBS symptoms than patients treated by hypnosis using standard 'gut-directed (...) ' hypnotherapy, and both would be superior to simple relaxation therapy.Patients (n = 51) with Rome II criteria were randomised to 'individualised' (holistic) hypnotherapy, standard 'gut-directed' hypnotherapy or relaxation therapy for a period of 11 weeks with two follow-up assessments at 2 weeks and at 3 months after the completion of the trial. The primary outcome was bowel symptom severity scale (BSSS).All the participants in this study improved their IBS symptoms (pain, bloating, constipation

2017 Health psychology open Controlled trial quality: uncertain

80. The connection between irritable bowel syndrome and lactose maldigestion or intolerance: a meta-analysis of clinical studies

The connection between irritable bowel syndrome and lactose maldigestion or intolerance: a meta-analysis of clinical studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO